Tesaro’s Zejula for Recurrent Ovarian Cancer Now Available in Germany

Tesaro’s Zejula for Recurrent Ovarian Cancer Now Available in Germany
Zejula (niraparib), an oral therapy for patients with recurrent ovarian cancer, is now available in Germany, according to Tesaro, the biopharma that developed the therapy. “The introductions of Zejula in Germany and the UK are significant milestones for TESARO as we bring transformative therapies to patients with cancer around the globe,” Orlando Oliveira, senior vice president and general

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *